The US Food and Drug Administration (FDA) has given final approval to market Zydus’s Venlafaxine Extended-Release Tablets, USP 37.5 mg, 75 mg, 150 mg and 225 mg Venlafaxine Hydrochloride Extended-Release Tablets. The company also received the final approval from FDA to market Pregabalin Extended-Release Tablets, USP 82.5 mg, 165 mg and 330 mg, a statement from Zydus Lifesciences has notified.
According to the statement, Venlafaxine is used to treat depression, anxiety, panic attacks and social anxiety disorder. It is expected to improve mood and energy levels in patients. The medication is also expected to decrease fear, anxiety, unwanted thoughts and the number of panic attacks. Pregabalin Extended-Release tablets are used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection. Both the drugs will be manufactured at the group’s formulation manufacturing facility at Ahmedabad, SEZ.